Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying

被引:19
作者
Kumar, V [1 ]
Kang, JC
Hohl, RJ
机构
[1] Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA
关键词
aqueous oxidized-cellulose colloids; camptothecin; microspheres; oxidized cellulose; spray-drying;
D O I
10.1081/PDT-100002254
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxidized celluloses (OC) containing 7, 13, and 20% carboxylic content (OC-7, OC-13, and OC-20, respectively) have been converted into aqueous colloidal dispersions and used to prepare microspheres of the antineoplastic agent camptothecin (CPT) by spray drying. Plasticizers used were glycerin, polyethylene glycol 400 (PEG-400), and polyethylene glycol 6000 (PEG-6000). Irrespective of the carboxylic content of OC and the nature of plasticizer employed, the size of microspheres varied from 1.25 +/-0.40 to 1.52 +/-0.47 mum. The release studies in pH 7.4 buffer revealed the dissolution of CPT to be faster from the microsphere formulations than from physical mixtures and free CPT The times to release 50% CPT (T-50%) from microspheres prepared using OC-7, OC-13, and OC-20 were about 31, 37, and 19 h, respectively. The in vitro cytotoxicity results indicated OC-20/CPT microspheres to be more effective than free CPT against human-derived RPMI-8402 lymphoid and THP-1 myeloid leukemia cell lines. The ED50 values for the OC-20/CPT microspheres and free CPT were 1 x 10(-5) anti 0.25 x 10(-1) mug/mL, respectively, against the RPMI-8402 line and 0.5 x 10(-2) and 0.75 mug/mL, respectively, against the THP-1 line. The higher activity of OC-20/CPT microspheres compared to that of the free drug is attributed to increased dissolution of CPT from microspheres.
引用
收藏
页码:459 / 467
页数:9
相关论文
共 39 条
[1]  
ABAEV A, 1992, ANTIBIOT MED BIOTEK, V31, P624
[2]  
Ashton HW, 1968, United States Patent, Patent No. [US3364200A, 3364200]
[3]  
BADESCHI A, 1997, DRUGS FUTURE, V22, P1259
[4]  
BURIS H, 1994, NEW DRUG THER, V8, P333
[5]   LIPOSOMAL STABILIZATION OF CAMPTOTHECINS LACTONE RING [J].
BURKE, TG ;
STAUBUS, AE ;
MISHRA, AK ;
MALAK, H .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (21) :8318-8319
[6]   THE STRUCTURAL BASIS OF CAMPTOTHECIN INTERACTIONS WITH HUMAN SERUM-ALBUMIN - IMPACT ON DRUG STABILITY [J].
BURKE, TG ;
MI, ZH .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :40-46
[7]   PREFERENTIAL BINDING OF THE CARBOXYLATE FORM OF CAMPTOTHECIN BY HUMAN SERUM-ALBUMIN [J].
BURKE, TG ;
MI, ZH .
ANALYTICAL BIOCHEMISTRY, 1993, 212 (01) :285-287
[8]  
CHEN LJ, 1993, Patent No. 636121
[9]   Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion [J].
Cortesi, R ;
Esposito, E ;
Maietti, A ;
Menegatti, E ;
Nastruzzi, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 159 (01) :95-103
[10]   Current perspectives on camptothecins in cancer treatment [J].
Dancey, J ;
Eisenhauer, EA .
BRITISH JOURNAL OF CANCER, 1996, 74 (03) :327-338